The Effects of Sclerostin on the Immune System

Autor: Jennifer O. Manilay, Cristine Donham
Rok vydání: 2020
Předmět:
0301 basic medicine
Endocrinology
Diabetes and Metabolism
Osteoimmunology
chemistry.chemical_compound
Mice
0302 clinical medicine
Bone Marrow
Cell differentiation
Extramedullary
Mice
Knockout
Myelopoiesis
B-Lymphocytes
Adipogenesis
Lymphopoiesis
Adaptor Proteins
Extramedullary hematopoiesis
Haematopoiesis
medicine.anatomical_structure
Hematopoiesis
Extramedullary
Public Health and Health Services
Cytokines
Stem cell
Knockout
Immunology
Clinical Sciences
030209 endocrinology & metabolism
Biology
Osteocytes
03 medical and health sciences
Wnt
Endocrinology & Metabolism
medicine
Animals
Humans
Wnt antagonists
Adaptor Proteins
Signal Transducing
Osteoblasts
Signal Transducing
Mesenchymal Stem Cells
medicine.disease
Hematopoietic Stem Cells
Hematopoiesis
030104 developmental biology
chemistry
Cancer research
Sclerostin
Bone marrow
Zdroj: Current osteoporosis reports, vol 18, iss 1
ISSN: 1544-2241
Popis: Purpose of reviewWe reviewed recent progress on the role of sclerostin (SOST) and its effects on the immune system in order to summarize the current state of knowledge in osteoimmunology, in regard to hematopoiesis, lymphopoiesis, and inflammation.Recent findingsChanges in sclerostin levels affect distinct niches within the bone marrow that support hematopoietic stem cells and B cell development. Sclerostin's regulation of adipogenesis could also be important for immune cell maintenance with age. Surprisingly, B cell development in the bone marrow is influenced by Sost produced by mesenchymal stem cells and osteoblasts, but not by osteocytes. Additionally, extramedullary hematopoiesis in the spleen and increased pro-inflammatory cytokine levels in the bone marrow are observed in global Sost-/- mice. In addition to changes in bone marrow density, sclerostin depletion affects B lymphopoiesis and myelopoiesis, as well as other changes within the bone marrow cavity that could affect hematopoiesis. It is therefore important to monitor for hematopoietic changes in patients receiving sclerostin-depleting therapies.
Databáze: OpenAIRE
Externí odkaz: